Last updated: September 3, 2026
The commercial opportunity for celecoxib and tramadol hydrochloride is concentrated in the fixed-dose combination Seglentis, marketed by Kowa Pharmaceuticals America. Seglentis contains 56 mg celecoxib and 44 mg tramadol hydrochloride per tablet and was approved by the FDA in October 2021 for acute pain in adults requiring an opioid analgesic when alternative treatments are inadequate [1]. The underlying ingredients are mature, generic products. The combination therefore competes on dosing convenience, opioid-sparing positioning, physician adoption, payer coverage, and patent protection rather than ingredient exclusivity.
Kowa does not publicly disclose Seglentis revenue as a standalone product. Its financial trajectory cannot be measured from audited product-level sales. The commercial profile is best assessed through FDA approval, prescription dynamics, controlled-substance restrictions, generic ingredient economics, patent duration, and the size of the acute-pain market.
What is Seglentis and how does the celecoxib-tramadol combination work?
Seglentis is an immediate-release oral tablet combining the nonsteroidal anti-inflammatory drug celecoxib with the opioid analgesic tramadol hydrochloride.
| Attribute |
Seglentis |
| Active ingredients |
Celecoxib 56 mg; tramadol hydrochloride 44 mg |
| Dosage form |
Immediate-release tablet |
| FDA approval |
October 15, 2021 |
| NDA |
NDA 214608 |
| Indication |
Acute pain in adults severe enough to require an opioid analgesic when alternatives are inadequate |
| Dosing |
Two tablets initially, followed by one tablet every 12 hours as needed |
| Maximum daily dose |
Four tablets, equal to celecoxib 224 mg and tramadol hydrochloride 176 mg |
| Controlled-substance status |
Schedule IV because of tramadol |
| Sponsor |
Kowa Pharmaceuticals America, Inc. |
The formulation uses two established analgesic mechanisms. Celecoxib inhibits cyclooxygenase-2 and reduces inflammatory pain. Tramadol provides centrally acting analgesic activity through opioid and monoaminergic pathways. The commercial proposition is that the combination can deliver analgesia while limiting exposure to each component relative to higher-dose single-agent therapy.
The product label limits use to short-term acute pain. It is not positioned as a chronic-pain maintenance product, which narrows recurring prescription volume but supports use after surgery, dental procedures, orthopedic injuries, and other acute pain events [1].
How large is the market for celecoxib and tramadol hydrochloride?
The ingredient markets are large but heavily commoditized. Celecoxib is available from multiple generic manufacturers in the United States. Tramadol hydrochloride is also broadly generic and is sold alone and in combination with acetaminophen.
| Market segment |
Competitive structure |
Pricing pressure |
Strategic implication |
| Generic celecoxib |
Multiple manufacturers |
High |
Low ingredient-level margin |
| Generic tramadol |
Multiple manufacturers |
High |
Low ingredient-level margin |
| Tramadol/acetaminophen |
Established generic combination |
High |
Strong substitute for acute pain |
| Seglentis |
Branded fixed-dose combination |
Lower direct competition at launch |
Requires differentiation and access investment |
| Other multimodal acute-pain regimens |
NSAIDs, acetaminophen, opioids, local anesthetics |
Moderate to high |
Broad clinical substitution |
Celecoxib entered the generic market after Pfizer’s U.S. exclusivity and patent barriers ended. Tramadol hydrochloride has been generic for many years. Neither ingredient provides a meaningful standalone growth engine for a branded combination.
Seglentis instead addresses a narrower opportunity: patients for whom clinicians want both anti-inflammatory and centrally acting analgesic activity in one prescription. The addressable population is limited by contraindications to NSAIDs, opioid-related prescribing controls, tramadol’s seizure and serotonin risks, and payer restrictions.
What is the financial trajectory for Seglentis?
Seglentis has a launch-stage commercial profile rather than a mature blockbuster profile. Kowa is a privately held Japanese pharmaceutical company and does not report Seglentis revenue in the manner of a publicly traded company with product-level segment disclosure. Publicly available regulatory materials identify approval, labeling, and safety information, but not net sales, prescription volume, gross-to-net deductions, or operating profit [1, 2].
The likely financial trajectory has four phases:
Launch and formulary development
The initial period after the 2021 approval required physician education, specialty-pharmacy access, payer contracting, and adoption in acute-pain settings. The product had to establish a clinical and economic rationale against low-cost generic celecoxib, tramadol, tramadol/acetaminophen, and separate-tablet regimens.
Controlled expansion
Growth depends on institutional protocols and prescriber familiarity. Surgical centers, dental practices, orthopedic practices, emergency departments, and pain specialists are potential channels. The fixed-dose format can reduce pill burden, but the two-tablet loading dose and 12-hour maintenance schedule limit the convenience advantage compared with some generic alternatives.
Margin pressure
A branded combination can command a price premium over generic ingredients only if insurers cover it or patients accept higher out-of-pocket costs. Any increase in prior authorization requirements can reduce prescription conversion. Discounting, copay support, and wholesale acquisition price management can also reduce net revenue.
Post-exclusivity erosion
Once competing products can rely on the same combination or an equivalent formulation, price erosion would likely be rapid because both active ingredients are generic and widely manufactured. The combination has no biologic complexity and no manufacturing barrier comparable to an injectable or modified-release product.
No public evidence establishes Seglentis as a material revenue contributor to Kowa. Product-level revenue claims would therefore be unsupported.
What patents protect celecoxib and tramadol hydrochloride products?
The principal commercial protection for Seglentis is expected to come from patents covering the combination formulation, composition, manufacturing process, or related pharmaceutical technology rather than from the original compound patents for celecoxib or tramadol.
The FDA Orange Book is the controlling public source for patents and exclusivity associated with an approved drug application. Seglentis should be evaluated through the Orange Book entry for NDA 214608, including listed patent numbers, use codes, and expiration dates [3].
| Protection category |
Seglentis relevance |
Expected competitive effect |
| Celecoxib compound patent |
Expired or commercially exhausted |
No protection for the ingredient alone |
| Tramadol compound patent |
Expired or commercially exhausted |
No protection for the ingredient alone |
| Fixed-dose composition patent |
Core potential barrier |
Can delay an identical combination product |
| Manufacturing patent |
Potential secondary barrier |
May complicate process replication |
| Method-of-use patent |
Possible protection for acute-pain use |
Narrower than composition protection |
| Regulatory exclusivity |
Limited relative to patent term |
Does not create long-term ingredient exclusivity |
| Formulation patent |
Relevant if specific tablet architecture is claimed |
Can affect ANDA design-around strategy |
Patent strength depends on claim scope, written-description support, obviousness risk, enablement, prosecution history, and whether an ANDA applicant can design around the protected formulation. A combination patent is usually weaker than a new chemical entity patent when the ingredients are already well known, particularly if prior art discloses coadministration or fixed-dose combinations of similar analgesics.
When does celecoxib and tramadol lose exclusivity?
The active ingredients already have generic competition. The relevant exclusivity question is when an applicant can challenge the Seglentis-specific patents and obtain FDA approval for a competing product.
The FDA approval date was October 15, 2021 [1]. Any New Chemical Entity exclusivity associated with the application would not ordinarily apply because celecoxib and tramadol were previously approved active ingredients. Seglentis therefore does not receive the four-year NCE exclusivity period applicable to a new molecular entity.
The practical exclusivity timeline is driven by:
- Listed Orange Book patent expiration dates.
- Any unexpired regulatory exclusivity attached to NDA 214608.
- Paragraph IV litigation and the resulting 30-month stay.
- The timing of ANDA submission and FDA review.
- The ability of generic applicants to use different strengths, tablet designs, or labeling.
A precise launch date cannot be inferred solely from the 2021 approval date. The Orange Book patent list and litigation record control the earliest legally available generic-entry scenarios.
What is the Orange Book status of Seglentis?
Seglentis is an FDA-approved prescription drug marketed under NDA 214608. Its Orange Book record is the relevant source for listed patents, therapeutic-equivalence information, and application data [3].
The Orange Book does not establish that a generic product is automatically blocked until every listed patent expires. An ANDA applicant can:
- File a Paragraph III certification and wait for patent expiration.
- File a Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed.
- Submit a Section VIII statement for a method-of-use patent and omit the protected indication.
- Develop a product that avoids the scope of a formulation or composition claim.
The commercial value of the patent estate therefore depends on enforceable claim breadth, not simply the number of listed patents.
Which companies are challenging celecoxib-tramadol exclusivity?
No publicly established Paragraph IV challenger or ANDA litigation outcome should be treated as confirmed without a current review of FDA records, district-court dockets, and the Orange Book. The generic manufacturers most capable of challenging the product are companies with established oral-solid-dose manufacturing and controlled-substance distribution, including large generic manufacturers and specialty pharmaceutical suppliers.
Potential challengers would evaluate:
- Whether the combination can be replicated without infringing formulation claims.
- Whether the 56 mg/44 mg strength is essential to the claims.
- Whether separate tablets can provide a legally and commercially viable alternative.
- Whether tramadol scheduling creates additional distribution and compliance costs.
- Whether the market is large enough to justify Paragraph IV litigation.
No biosimilar pathway applies. Seglentis is a small-molecule tablet, not a biologic. Competition would proceed through an ANDA, a 505(b)(2) application, or ordinary generic substitution rules, not through the abbreviated biosimilar pathway.
What formulations and methods of use are commercially protected?
The most relevant formulation issue is the fixed-dose tablet containing celecoxib and tramadol hydrochloride at the approved strength. Protection may extend to:
- The ratio of celecoxib to tramadol.
- Tablet composition and excipient selection.
- Dissolution or release characteristics.
- Stability and manufacturing parameters.
- Methods of treating acute pain with the combination.
- Dosing schedules that use the two-drug product.
Method-of-use protection has less commercial value than composition protection if physicians can prescribe the product for an unclaimed use or if an ANDA applicant uses a Section VIII statement. A composition claim can block the same product across multiple indications, but its validity may be challenged on obviousness grounds because both active ingredients were established analgesics before the combination was developed.
What litigation and settlement risks affect Seglentis?
Patent litigation risk is concentrated around future ANDA filings. The likely sequence is:
| Event |
Business impact |
| Paragraph IV notice |
Triggers potential Hatch-Waxman litigation |
| Patent suit within 45 days |
Can create a 30-month FDA approval stay |
| Claim-construction and validity rulings |
Determine launch timing |
| Settlement agreement |
May establish an agreed generic-entry date |
| Trial or appellate decision |
Can accelerate or delay entry |
| Commercial launch |
Causes price and volume erosion |
No confirmed public settlement should be assigned to Seglentis without a filed agreement or court record. A private settlement can preserve branded revenue while giving a generic manufacturer a defined future launch date, but the financial value depends on the negotiated entry date, authorized-generic provisions, and any volume or supply arrangements.
How does Seglentis compare with generic celecoxib and tramadol?
| Factor |
Seglentis |
Separate generic therapy |
| Pill burden |
Lower after dosing is established |
Usually two products |
| Cost |
Branded premium likely |
Low generic cost |
| Dose flexibility |
Fixed 56 mg/44 mg ratio |
Greater independent titration |
| Prescribing control |
Tramadol Schedule IV applies |
Tramadol controls still apply |
| Formulary access |
Requires branded coverage |
Broad generic coverage |
| Clinical positioning |
Multimodal acute pain |
Customizable regimen |
| Patent exposure |
Combination patents |
Ingredient patents largely expired |
| Generic-entry risk |
Concentrated after patent challenge |
Already present |
The fixed-dose product has a convenience advantage but loses flexibility. Clinicians may prefer separate generic products when they need to adjust celecoxib and tramadol independently or avoid one ingredient.
What geographic markets and manufacturing barriers matter?
The principal commercial opportunity is the United States because Seglentis received FDA approval and its sponsor has U.S. commercialization rights. International opportunities depend on separate regulatory filings, local opioid controls, NSAID labeling requirements, reimbursement, and patent status.
Manufacturing barriers are moderate. The product is an oral solid dose using well-established active ingredients. Manufacturing requires controlled-substance compliance for tramadol, validated content uniformity, dissolution control, stability testing, and supply-chain security. Those requirements raise operational complexity but do not create a durable barrier for experienced generic manufacturers.
Key Takeaways
- Seglentis is the relevant branded product combining celecoxib and tramadol hydrochloride.
- FDA approval occurred on October 15, 2021, under NDA 214608.
- Celecoxib and tramadol are mature generic ingredients with substantial price competition.
- Kowa does not publicly report standalone Seglentis revenue, so product-level financial performance cannot be quantified from audited disclosures.
- Commercial growth depends on acute-pain adoption, payer access, controlled-substance prescribing, and differentiation from separate generic tablets.
- The key intellectual-property assets are combination, formulation, manufacturing, and method-of-use patents.
- No biosimilar risk exists because Seglentis is a small-molecule oral tablet.
- Future generic entry will depend on Orange Book patents, Paragraph IV challenges, litigation, settlements, and design-around options.
- The product has moderate manufacturing complexity but no biologic or injectable barrier.
- Long-term revenue erosion would likely be rapid after legally authorized generic or ANDA entry because the underlying ingredients are already commoditized.
FAQs
Is Seglentis the same as taking celecoxib and tramadol separately?
No. Seglentis provides a fixed 56 mg celecoxib and 44 mg tramadol hydrochloride dose per tablet. Separate prescriptions allow independent dose adjustment and may have different reimbursement and substitution rules.
Is tramadol in Seglentis an opioid?
Yes. Tramadol is an opioid analgesic and a Schedule IV controlled substance in the United States. Seglentis carries opioid-related warnings, including risks of addiction, misuse, respiratory depression, serotonin syndrome, seizures, and neonatal opioid withdrawal [1].
Can a generic company copy Seglentis before all patents expire?
Potentially. An ANDA applicant can file a Paragraph IV certification, challenge listed patents, or design around formulation claims. FDA approval and commercial launch depend on litigation, patent scope, regulatory review, and any settlement agreement.
Does Seglentis have biosimilar competition?
No. Biosimilars apply to biological products. Seglentis is a chemically synthesized small-molecule tablet and would face generic-drug competition instead.
What is the main commercial weakness of celecoxib-tramadol fixed-dose therapy?
The main weakness is the tradeoff between convenience and dose flexibility. Generic separate-tablet regimens are cheaper and allow clinicians to adjust or discontinue either active ingredient independently.
References
-
U.S. Food and Drug Administration. (2021). Seglentis prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214608s000lbl.pdf
-
Kowa Pharmaceuticals America, Inc. (2021). Kowa announces FDA approval of Seglentis for the management of acute pain. https://www.kowapharma.com
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
